Profluent Bio
Company Type: Therapeutic development
Main focus: Using AI to optimise the design of gene editors for novel therapeutics
Company stage: Pre-clinical
Diseases:
Genome-editing tool: OpenCRISPR-1
Funding stage: Venture - Series Unknown
Location: Berkeley, California, USA
Website: https://www.profluent.bio/
Pipeline:
Partners:
Profluent Bio is a biotechnology startup focused on leveraging AI to optimise protein engineering for gene editing. The company's principal project, OpenCRISPR, aims to revolutionise CRISPR technology by designing novel, AI-generated CRISPR proteins. OpenCRISPR is the world’s first open source, AI generated gene editor and has demonstrated precision editing of the human genome. OpenCRISPR-1 launched earlier this year as an open-source, freely available to licence, customisable gene editor designed with AI.